Divarasib is improving the existing data in PFS , OS and ORR in KRAS G12C NSCLC in the Krascendo 1 trial. A really good news for our patients!

Christian Rolfo· @ChristianRolfo · X·2026-10-25 23:47· 1 天前评分70

正文 · 原文

Divarasib is improving the existing data in PFS , OS and ORR in KRAS G12C NSCLC in the Krascendo 1 trial. A really good news for our patients!
Congrats @FSkoulidis & team! Simultaneous publication in @NEJM
Excellent discussion @BenjaminBesseMD
@KRASKickers
@myESMO
#ESMO26

38 浏览 · 1 赞 · 0 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Christian Rolfo · x.com